The Federal Trade Commission (FTC) under Chair Lina Khan took an aggressive approach to tackling anticompetitive behavior in ...
The court held that those patents did not satisfy the requirements for listing in the Orange Book, finding that the patents did not claim the drug or drug product for which the associated New Drug ...
Advancing two pivotal Phase 3 trials of BXCL501 for acute treatment of agitation associated with bipolar disorders, ...
The drug and device industries have a lot hinging on the results of the Nov. 5 U.S. presidential and congressional elections.
Trump has not been vocal about healthcare policies but indicated that RFK Jr will have a big influence on the sector.